Home > GAMMAGARD Products > GAMMAGARD LIQUID SC > Consistency

Consistency
GAMMAGARD LIQUID - SC Administration

Protecting life's moments with consistent trough levels1,2

In the SC administration of GAMMAGARD LIQUID clinical study1

  • The median Ig trough level during intravenous treatment was 1010 mg/dL (95% CI: 940-1240)
  • The mean Ig trough level during intravenous treatment was 1050 ± 260 mg/dL2
  • The median Ig trough level during subcutaneous treatment was 1260 mg/dL (95% CI: 1060-1400)a
  • The mean Ig trough level during subcutaneous treatment was 1202 ± 282 mg/dLa

aTaken from pharmacokinetic analysis at the end of study period 4.

 

Study Design1,2

  • Multicenter, prospective, open-label, study (N=49 adults [n=31 16 years or older], adolescents [n=4 between 12 years and <16], and children [n=14 between 2 years and <12])
  • 4 study periods + optional extension

  • Mean weekly subcutaneous doses ranged from 182-191 mg/kg

Recommended dosing1

Important Considerations for Dosing1

  • Adjust dose according to IgG levels and clinical response as the frequency and dose of IgG treatment may vary from patient to patient
  • The patient's clinical response should be the primary consideration in dose adjustment

References: 1. GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% [Prescribing Information]. Westlake Village, CA: Baxalta US Inc. 2. Wasserman RL, Melamed I, Kobrynski L, et al. Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease. J Clin Immunol. 2011;31(3):323-331.


  • Your patients can get access to experienced Patient and Nurse Advocates, insurance and financial support, useful tools, and more.
    Find Out How
  • Clinical Study Video Learn more about the clinical study of the subcutaneous administration of GAMMAGARD LIQUID.
    View study presentation
Error processing SSI file